Apigenin as a CD38 inhibitor in NAD metabolism models

Objective: To evaluate apigenin as a potential modulator of CD38 activity and NAD metabolism. Biochemical assays and cellular models were used to determine whether apigenin inhibits CD38-mediated NAD consumption and alters downstream metabolic signaling. The study found that apigenin reduced CD38 activity in a dose-dependent manner in selected model systems, leading to preservation of intracellular NAD pools and changes in related sirtuin-linked pathways. These effects were interpreted as a plausible mechanism for apigenin's broader interest in aging and metabolic research. The work also emphasized that potency depends strongly on assay conditions and compound exposure, and that dietary apigenin likely produces far lower concentrations than those used in vitro. Nonetheless, the data identify CD38 as a mechanistically relevant target and help explain why apigenin has been considered a candidate nutraceutical scaffold. Further work is needed to determine whether the observed biochemical effects translate into meaningful in vivo outcomes.